```php Orforglipron Foundayo Diabetes Trial Results | James Whynot MD
Diabetes & Weight Management

Orforglipron: A New Oral GLP-1 Option Showing Strong Diabetes and Weight-Loss Results

Updated June 2026

Orforglipron, marketed as Foundayo, is an oral GLP-1 receptor agonist being studied for type 2 diabetes and weight management. Unlike injectable GLP-1 medications, orforglipron is taken by mouth. It is also different from oral semaglutide because it does not require the same food and water timing restrictions.

New phase 3 clinical trial results from the ACHIEVE program showed that orforglipron produced meaningful improvements in blood sugar control and body weight in adults with type 2 diabetes.

Key Points

  • Orforglipron is an oral, nonpeptide GLP-1 receptor agonist.
  • In clinical trials, it lowered A1c more than dapagliflozin and oral semaglutide.
  • It also produced greater weight loss than the comparison medications in the reported trials.
  • Gastrointestinal side effects were common and led to more treatment discontinuation than comparison drugs.
  • It may become an important oral option for patients who prefer not to use injections.

Why Orforglipron Is Important

Current GLP-1 medications have changed the treatment of obesity and type 2 diabetes. However, many of the strongest agents are injectable medications. An effective pill could make GLP-1 therapy easier for many patients, especially those who are reluctant to use injections.

Orforglipron is also a nonpeptide medication. This may eventually make it easier to manufacture compared with peptide-based GLP-1 drugs.

Practical advantage: Orforglipron is taken by mouth and does not have the same strict fasting, food, and water instructions required with oral semaglutide.

ACHIEVE-2: Orforglipron Compared With Dapagliflozin

Study Design

ACHIEVE-2 included adults with type 2 diabetes taking metformin. Participants received different doses of orforglipron or dapagliflozin.

Results

  • Orforglipron lowered A1c more than dapagliflozin.
  • Higher doses of orforglipron produced greater weight loss.
  • Gastrointestinal side effects were more common with orforglipron.
  • No severe hypoglycemia episodes were reported.

ACHIEVE-3: Orforglipron Compared With Oral Semaglutide

Study Design

ACHIEVE-3 compared orforglipron with oral semaglutide in adults with type 2 diabetes who were taking metformin.

Results

  • Both studied doses of orforglipron lowered A1c more than oral semaglutide.
  • Orforglipron met the study goal of noninferiority and also showed superiority in A1c reduction.
  • Gastrointestinal side effects were more frequent with orforglipron.
  • More patients stopped orforglipron because of adverse effects compared with oral semaglutide.

ACHIEVE-5: Orforglipron Added to Insulin Glargine

Study Design

ACHIEVE-5 studied adults with type 2 diabetes already using insulin glargine, with or without metformin or an SGLT2 inhibitor.

Results

  • All tested doses of orforglipron lowered A1c more than placebo.
  • Patients taking orforglipron also lost more weight than those taking placebo.
  • Most side effects were gastrointestinal and were generally mild to moderate.
  • Orforglipron did not increase clinically significant hypoglycemia compared with placebo.

Where Might Orforglipron Fit?

Orforglipron may fit into treatment in situations where a GLP-1 receptor agonist is appropriate, but the patient prefers a pill rather than an injection. It may be especially attractive for patients who want the metabolic benefits of GLP-1 therapy but have difficulty accepting injectable treatment.

However, it should not be viewed as a replacement for SGLT2 inhibitors in patients who need kidney or heart failure protection. SGLT2 inhibitors remain important medications with proven organ-protective benefits.

Important clinical point: Choosing between a GLP-1 medication, an SGLT2 inhibitor, insulin, metformin, or combination therapy depends on the patient’s A1c, weight goals, kidney function, cardiovascular history, medication tolerance, insurance coverage, and personal preferences.

Side Effects to Watch For

As with other GLP-1 receptor agonists, the most common side effects reported with orforglipron were gastrointestinal.

In the ACHIEVE trials, gastrointestinal symptoms were usually mild to moderate, but they were common enough that more patients discontinued orforglipron compared with the comparator drugs.

Bottom Line

Orforglipron appears to be a promising oral GLP-1 receptor agonist for type 2 diabetes and weight management. The ACHIEVE studies showed strong A1c lowering and meaningful weight loss, including results that compared favorably with dapagliflozin and oral semaglutide.

The main limitation is tolerability. Gastrointestinal side effects were more common with orforglipron, and more patients stopped treatment because of adverse effects. Even so, an effective oral GLP-1 medication without strict food and water restrictions could become an important option for many patients.

This article is for general educational purposes only and is not a substitute for medical advice. Patients should discuss diabetes and weight-loss medication options with their own medical clinician before starting, stopping, or changing treatment.

```